Vanguard Group Inc. Increases Stock Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK)

Vanguard Group Inc. boosted its stake in Scholar Rock Holding Co. (NASDAQ:SRRK) by 17.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,743,482 shares of the company’s stock after acquiring an additional 708,817 shares during the period. Vanguard Group Inc. owned 0.05% of Scholar Rock worth $205,013,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the stock. American Century Companies Inc. bought a new position in Scholar Rock in the fourth quarter worth about $28,394,000. Exome Asset Management LLC bought a new position in shares of Scholar Rock in the 3rd quarter worth approximately $1,115,000. Geode Capital Management LLC lifted its stake in shares of Scholar Rock by 8.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,543,025 shares of the company’s stock valued at $12,361,000 after purchasing an additional 120,489 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Scholar Rock by 23.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 622,409 shares of the company’s stock valued at $26,901,000 after purchasing an additional 119,616 shares in the last quarter. Finally, Barclays PLC grew its stake in Scholar Rock by 103.4% in the third quarter. Barclays PLC now owns 165,449 shares of the company’s stock worth $1,324,000 after purchasing an additional 84,118 shares during the period. 91.08% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director Katie Peng sold 1,006 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $34.42, for a total value of $34,626.52. Following the transaction, the director now directly owns 30,319 shares of the company’s stock, valued at approximately $1,043,579.98. This represents a 3.21 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Jing L. Marantz sold 5,655 shares of Scholar Rock stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $44.20, for a total value of $249,951.00. Following the completion of the sale, the insider now directly owns 67,200 shares of the company’s stock, valued at approximately $2,970,240. The trade was a 7.76 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 299,772 shares of company stock worth $11,245,798 over the last three months. 19.20% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Separately, Wedbush restated an “outperform” rating and set a $50.00 target price on shares of Scholar Rock in a report on Tuesday, March 25th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $42.67.

Scholar Rock Stock Down 12.4 %

Shares of NASDAQ:SRRK opened at $26.90 on Friday. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63. The stock has a fifty day simple moving average of $36.31 and a two-hundred day simple moving average of $33.83. Scholar Rock Holding Co. has a 12-month low of $6.76 and a 12-month high of $46.98. The stock has a market capitalization of $2.55 billion, a price-to-earnings ratio of -11.45 and a beta of 0.56.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.